KaydedilenlerDerginizi ekleyin

Dergiler / Epilepsi / 2021 / Cilt: 27 - Sayı: 4

Effects of Carbamazepine On Vascular Risk Factors and Atherosclerosis in Epileptic Children

Seyithan TAYSI
Osman BASPINAR
Ayşe Aysima OZCELIK
Asli Imran YILMAZ
Sayfa
226–231
Yayın Tarihi
2022-10-17
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

We think that these findings enhance our understanding of the relationship between oxidative stress and antiepileptic drugs

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Objectives: The aim of our study was to investigate the presence of increased cardiovascular risk in epileptic children treated with carbamazepine.
📊
Temel Bulgular & Veri:Methods: Twenty-one children aged between 2 and 16 years with epilepsy who were treated with carbamazepine were included in the study.
💡
Sonuç & Katkı:We think that these findings enhance our understanding of the relationship between oxidative stress and antiepileptic drugs
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Abstract

Objectives: The aim of our study was to investigate the presence of increased cardiovascular risk in epileptic children treated with carbamazepine. This study was designed to evaluate the relation of carbamazepine and atherosclerosis by investigating the effect of carbamazepine on antioxidant capacity, lipid profile, oxidized low-density lipoprotein (LDL), and carotid artery intima-media thickness (C-IMT). Methods: Twenty-one children aged between 2 and 16 years with epilepsy who were treated with carbamazepine were included in the study. Triglyceride, total cholesterol, high-density lipoprotein, LDL, lipid hydroperoxide, paraoxonase, arylesterase levels, and C-IMT were measured in all patients before the treatment, at the 3rd and 6th months of the treatment. Results: Thirteen (61.9%) of the patients were male, and 8 (38.1%) were female. The mean age of the patients was 111.48±44.81 months. There was a significant increase in total cholesterol, arylesterase, and paraoxonase levels at the 6th months of the treatment compared with pre-treatment levels. No significant changes were observed in C-IMT values. Conclusion: Our study is the first study in the literature in which the relation between arylesterase and paraoxonase levels and CIMT in pediatric patients before and after carbamazepine treatment was prospectively investigated. The exact mechanism of carbamazepine on atherosclerosis is not clearly understood. These results demonstrate that these patients could be at increased risk of the development of cardiovascular complications. In light of these findings, future studies in epileptic children should be to plan antioxidant capacity, cholesterol level, and measuring C-IMT with ultrasonography periodically in long term. We think that these findings enhance our understanding of the relationship between oxidative stress and antiepileptic drugs

🔖

Bu Makaleye Atıf Yap

TAYSI, S., BASPINAR, O., OZCELIK, A. A., YILMAZ, A. I. (2022). Effects of Carbamazepine On Vascular Risk Factors and Atherosclerosis in Epileptic Children. Epilepsi, Cilt: 27 - Sayı: 4, 226–231. https://ajindex.com/articles/501628

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (15)

  1. Verrotti A, Basciani F, Domizio S, Sabatino G, Morgese G, Chiarelli F. Serum lipids and lipoproteins in patients treated with antiepileptic drugs. Pediatr Neurol 1998;19(5):364–7
  2. Adams RD, Victor M. Epilepsy and other Seizure Disorders in Principles of Neurology. 5th ed. New York: McGraw Hill; 1993. p. 273-99
  3. Ferlisi M, Hocker S, Trinka E, Shorvon S; International Steering Committee of the StEp Audit. Etiologies and characteristics of refractory status epilepticus cases in different areas of the world: Results from a global audit. Epilepsia 2018;59 Suppl 2:100–7
  4. Serdaroğlu A, Ozkan S, Aydin K, Gücüyener K, Tezcan S, Aycan S. Prevalence of epilepsy in Turkish children between the ages of 0 and 16 years. J Child Neurol 2004;19(4):271–4
  5. Al Khalili Y, Sekhon S, Jain S. Carbamazepine Toxicity. Treasure Island, FL: StatPearls Publishing; 2021
  6. Zhuo L, Zhang Y, Zielke HR, Levine B, Zhang X, Chang L, et al. Sudden unexpected death in epilepsy: Evaluation of forensic autopsy cases. Forensic Sci Int 2012;223(1–3):171–5
  7. Devinsky O, Kim A, Friedman D, Bedigian A, Moffatt E, Tseng ZH. Incidence of cardiac fibrosis in SUDEP and control cases. Neurology 2018:3;91(1):e55–61
  8. Hamed SA, Hamed EA, Hamdy R, Nabeshima T. Vascular risk factors and oxidative stress as independent predictors of asymptomatic atherosclerosis in adult patients with epilepsy. Epilepsy Res 2007;74(2–3):183–92
  9. Navab M, Fogelman AM, Berliner JA, Territo MC, Demer LL, Frank JS, et al. Pathogenesis of atherosclerosis. Am J Cardiol 1995;76(9):18C–23
  10. Durrington PN, Mackness B, Mackness MI. Paraoxonase and atherosclerosis. Arterioscler Thromb Vasc Biol 2001 Apr;21(4):473- 80
  11. Halliwell B, Chirico S. Lipid peroxidation: İts mechanism, measurement, and significance. Am J Clin Nutr 1993;57(Suppl 5):715S–24; discussion 724S–5
  12. Fisher RS, Acevedo C, Arzimanoglou A, Bogacz A, Cross JH, Elger CE, et al. ILAE official report: A practical clinical definition of epilepsy. Epilepsia 2014;55(4):475–82
  13. Fisher RS, Cross JH, D’Souza C, French JA, Haut SR, Higurashi N, et al. Instruction manual for the ILAE 2017 operational classification of seizure types. Epilepsia 2017;58(4):531–42
  14. Sözüer DT, Atakil D, Dogu O, Baybas S, Arpaci B. Serum lipids in epileptic children treated with carbamazepine and valproate. Eur J Pediatr 1997;156(7):565–7
  15. Harit D, Aggarwal A, Kalra S, Chhillar N. Effect of carbamazepine and valproate monotherapy on cardiovascular risks in epilepti